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Abstract. The clinical picture of patients with sickle cell anemia (SCA) is associated with several
complications some of which could be fatal. The objective of this study is to analyze the causes of
death and the effect of sex and age on survival of Brazilian patients with SCA. Data of patients
with SCA who were seen and followed at HEMORIO for 15 years were retrospectively collected
and analyzed. Statistical modeling was performed using survival analysis in the presence of
competing risks estimating the covariate effects on a sub-distribution hazard function. Eight
models were implemented, one for each cause of death. The cause‐specific cumulative incidence
function was also estimated. Males were most vulnerable for death from chronic organ damage
(p = 0.0005) while females were most vulnerable for infection (p=0.03). Age was significantly
associated (p ≤ 0.05) with death due to acute chest syndrome (ACS), infection, and death during
crisis. The lower survival was related to death from infection, followed by death due to ACS. The
independent variables age and sex were significantly associated with ACS, infection, chronic
organ damage and death during crisis. These data could help Brazilian authorities strengthen
public policies to protect this vulnerable population.
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Introduction. The clinical picture of patients with
sickle cell anemia (SCA) is associated with several
complications some of which could be fatal.1-3 Besides
the recurrent episodes of acute vaso-occlusive crises
(VOCs), these complications include, among other
things, stroke, acute chest syndrome, splenic and

hepatic sequestration, infections, priapism, leg ulcers,
retinopathy,
avascular
necrosis,
cholelithiasis,
progressive organ failure and death.3 The frequency
and severity of these complications vary with age, time
and sex. Ischemic stroke, for example, is more
common in children whereas leg ulcers are more
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common in adults.3 The probability of the recurrence of
each complication at a certain age has not been well
studied. The objective of this study is to analyze the
causes of death using the competitive risk statistical
model.4 This analysis is based on the recently reported
retrospective data on the pattern of morbidity and
mortality in children, adolescents and adults in Rio de
Janeiro, Brazil.5
Material and Methods.
Patients: Retrospective data were collected and
analyzed in patients with SCA including patients with
sickle-β0-thalassemia (Sβ0thal), who were seen and
followed at HEMORIO for 15 years from January 1,
1998, through December 31, 2012. Children and adults
were included in the study. The total number of
patients enrolled was 1676. The diagnosis of SCA
including sickle-β0-thalassemia was confirmed by highperformance liquid chromatography (HPLC). The date
and cause of death were confirmed from the patients’
charts if death occurred at HEMORIO. Death outside
HEMORIO was suspected if patients failed to show up
for follow-up and confirmed by interviews with the
patients’ families and from death certificates. None of
the patients was taking hydroxyurea. The study was
approved by the Institutional Review Board (IRB) of
HEMORIO.
Statistical analysis. Statistical modeling was performed
using Survival analysis in the presence of competing
risks.
Basically, three functions are used in survival data:
the survival function, the cumulative distribution
function, and the hazard function.
In survival analysis, it is common to investigate the
lifetime related to a single cause of death. However,
there are more complex models, in which the death of
the individual is related to one of several possible
causes identified in the study. These models are called
competing risk models being suitable in studies where
individuals are exposed to more than one cause of
failure or event.
Gooley et al.6 define the competing risk as a
survival model in which the occurrence of an event
prevents or alters the probability of occurrence of
another event.
In general, three types of approach are used in the
presence of competing risks:6 1 - Event-free survival
model, using the Cox model4 considering the time until
the occurrence of the first event. This model is not
suitable because it does not consider the various risk
factors; 2 – Cause-specific hazard model, where the
Cox model is used considering one of the events as the
main cause and the rest are censored. This approach is
also unsuitable because it is not possible to estimate the
common effect of a covariate for competing outcomes.
Additionally, the sum of the cumulative distribution

function for each outcome is different from the
cumulative distribution function of the overall curve. It
would also be necessary to be valid the assumption of
independence between the event of interest and other
competing events, considered censorship, which rarely
occurs; and 3 – Hazard of subdistribution model, using
the cumulative incidence function. This model does not
require any assumption of independence of competing
risks.7
The
cumulative
incidence
function,
or
subdistribution function, introduced by Kalbleisch &
Prentice,8 is defined as the joint probability
𝐹𝑖 (𝑡) = 𝑃(𝑇 ≤ 𝑡, 𝐶 = 𝑖), 𝑖 = 1, ⋯ , 𝑝
That is, 𝐹𝑖 (𝑡) is the probability of failure for a
specific cause, among p possible causes over time.
Fine and Gray9 proposed a regression model
implemented on the cumulative incidence function for
analyzing competing risks. Modeling is performed by
hazard of subdistribution function, defined as the
instantaneous hazard of an individual suffering the
event for a specific cause, conditional to have survived
until a certain time t.
γ(𝑡|𝑧) = 𝑒𝑥𝑝(𝛽 ′ 𝑧)𝛾0 (𝑡)
Where γ is the hazard of subdistribution; 𝛾0 is the
baseline hazard of the subdistribution; 𝛽 is a vector of
coefficients to be estimated; and 𝑧 is the vector of
independent variables.
The partial likelihood function is modeled as an
extension of the Cox proportional hazards model,10
weighted by 𝑤𝑖𝑗 .
𝑟

ℒ̃(𝛽) = ∏ (
𝑗=1

𝑒𝑥𝑝(𝛽𝑧𝑗 )
)
∑𝑖∈𝑅𝑗 𝑤𝑖𝑗 𝑒𝑥𝑝(𝛽𝑧𝑖 )

In this model, a patient who has suffered a
competing risk is not removed from the risk set. This
individual receives a 𝑤𝑖𝑗 =

𝐺̂ (𝑡𝑗 )
𝐺̂ (𝑚𝑖𝑛(𝑡𝑖 ,𝑡𝑗 ))

weight, where

𝐺̂ is the nonparametric Kaplan-Meier11 distribution of
the censorship. The weight 𝑤𝑖𝑗 is decreasing due to the
decay of the Kaplan-Meier curve. The distribution of
the censorship is given by the pair (𝑇𝑖 , 𝐶𝑖 ), and 𝑇𝑖 is the
time measured until the occurrence of the first
competing event; and 𝐶𝑖 = 0 if it is observed the
occurrence of some type of event and 𝐶𝑖 = 1 if no
event occurs.12 Thus, there is an inversion of the usual
concepts of event and censorship.
In each instant 𝑡𝑗 , in which the event of interest has
been observed, the risk set is composed of individuals
who have not suffered any event until the time 𝑡𝑗 ,
receiving the weight 𝑤𝑖𝑗 = 1; and those who have
suffered a competing event before this time 𝑡𝑗 being
weighted as 𝑤𝑖𝑗 ≤ 1. Thus, given the occurrence of the
event of interest in time 𝑡𝑗 , for each individual who has
suffered a competing event in 𝑡𝑗 , the greater the
distance between points 𝑡𝑖 and 𝑡𝑗 , the lower the weight
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Table 1. Risk of subdistribution regression model.

Acute Chest Syndrome
(n.º of events: 71)
Infection
(n.º of events: 82)
Stroke
(n.º of events: 33)
Cardiac Causes
(n.º of events: 13)
Chronic Organ Damage
(n.º of events: 30)

Coefficient

Relative Risk

Lower 95% CI

Upper 95% CI

p

Female

-0.3033

0.7384

0.4623

1.1793

0.2042

Age

-0.0385

0.9623

0.9418

0.9832

0.0004

Female

0.5000

1.6487

1.0496

2.5897

0.0300

Age

-0.0194

0.9807

0.9621

0.9997

0.0467

Female

-0.4294

0.6509

0.3260

1.2995

0.2235

Age

-0.0154

0.9847

0.9558

1.0145

0.3102

Female

0.6576

1.9301

0.5933

6.2791

0.2746

Age

0.0176

1.0177

0.9724

1.0652

0.4500

Female

-1.5853

0.2049

0.0837

0.5016

0.0005

Age

0.0282

1.0286

0.9991

1.0589

0.0575

𝑤𝑖𝑗 .12
Results. The causes of death of the 281 patients who
died were analyzed. The most common causes of death
included infection mostly due to sepsis, acute chest
syndrome (ACS), overt stroke, sudden during crisis and
organ damage due to hepatic or renal failure. Thirteen
patients died of unrelated causes mostly due to trauma.
In this work, survival analysis was performed using
the risk of sub-distribution regression model.9 These
models consider the cumulative incidence function,
using a weighting factor for each individual
considering all outcomes. Thus, the individual who
suffers from the competing event is not censored
receiving a weight that decreases gradually with time.
Eight models were implemented, one for each cause
of death related to SCDA, as shown in Table 1: Acute
Chest Syndrome, Infection, Stroke, Cardiac Causes,
Chronic Organ Damage, Death During Crisis, Other
(Splenic Sequestration, Hemolytic Crisis or Hepatic
Crisis) and Unknown.
It is observed that the males are most vulnerable for
death from chronic organ damage (p = 0.0005) while
females are most vulnerable for death from infection
(p=0.03). Sex did not show a statistically significant
association with other causes of death. Age is
significantly (p ≤ 0.05) associated with death due to
ACS, infection, and death during crisis. The increase of
one year in age corresponds to a 3.8% reduction in the
risk of death by ACS; 1.9% in the risk of death from
infection; and 6.2% for death during crisis. On the
other hand, the increase of one year in age implies an
increase of 2.8% in the risk of death from chronic
organ damage, at a significance level of 10%.
Figure 1 shows the cumulative incidence function,
where one can observe that the lower survival is related
to death from infection, followed by death due to ACS.
Compared to the model of competing risks, the
independent variables age and sex were significantly
associated with the outcomes with an asterisk.

Figure 1.

Analyses were performed with the use of packages
“cmprsk” 13 and “mstate” 14-16 of R software.17
Discussion. Despite all Brazilian efforts, the mortality
of patients with SCA is still very high in Brazil.2,3
These efforts included, among other things, newborn
screening, penicillin/antibiotic prophylaxis, vaccination
including anti-pneumococcus, anti-meningococcus,
annual anti-influenza, blood transfusion and
transcranial doppler determinations.3,5,18 In this study,
we used the competitive risk analysis to evaluate the
causes of mortality among our cohort.
A competing risk is an event whose occurrence
either precludes the occurrence of another event under
examination or fundamentally alters the probability of
occurrence of this other event, so it is an ideal model to
analyze causes of death in a specific disease with
multiple possible causes of death as in SCD.6 It was
used before in other chronic disease but never is SCD
in Brazil before.19
The competitive risk model was used because it is
adequate in survival analysis when there are mutually
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exclusive events, that is when the occurrence of one
event prevents another event occurring. In the article,
events are deaths from various causes. The cumulative
incidence function (represented by the graph) evaluates
for each patient the probability of occurrence of a
specific event before a certain time t. The risk subdistribution model estimates the effect of independent
variables for each specific event, considering the
presence of competitive risks.
The reasons for the relatively low death rate of
females due to chronic organ damage are unknown.
Possibilities include gender differences in nitric oxide
availability,20 and the influence of the X-chromosome
linked hemoglobin (Hb) F gene21 which may be
protective against organ damage in females. However,
Dover’s et al. study was not confirmed by additional
studies. In addition, the increase in Hb F by the X-

chromosome is minimal in comparison to other studies
indicating that Hb F has to be as high as ≥ 8% to be
effective. Other determinants of survival such as
hyperviscosity, alpha genotypes, and beta haplotypes
could not be determined at HEMORIO.
Conclusions. Mortality among patients with SCD
using the competing risks of death was evaluated for
the first time in a single institution in Rio de Janeiro,
Brazil.
In this article, we used the subdistribution hazard
function which evaluates the effect of covariates on the
cumulative incidence function for each of the
competitive events. This modeling is advantageous
because it makes no assumption about the
independence of competitive events.
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